CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals today announced that it will present preclinical data on its first-in-class selective cyclin-dependent kinase 7 (CDK7) program in acute leukemias at the American Society of Hematology (ASH) Annual Meeting taking place December 5-8 in Orlando, Florida.
CDK7 Inhibition as a Novel Treatment Strategy for Acute Leukemias
Certain cancers, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), are dependent on high and constant expression of transcription factors for their growth and survival, and have been shown to be particularly sensitive to selective inhibition of the transcriptional kinase CDK7. The poster presentation at ASH details preclinical in vitro and in vivo data demonstrating that the Company’s selective and potent CDK7 inhibitors preferentially kill cancer cells over normal cells and induce significant tumor regression in patient-derived xenograft models of AML and ALL.
|Date & Time:||Saturday, Dec. 5, from 5:30-7:30 p.m. EST|
Targeting Transcriptional Dependency in Acute Myeloid Leukemia (AML) with a Covalent Inhibitor of Transcriptional Kinase CDK7
|Session Title:||616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I|
|Presenter:||Yoon J. Choi, Ph.D., Senior Scientist, Syros Pharmaceuticals|
|Location:||Orange County Convention Center, Hall A|
About Syros Pharmaceuticals
Syros Pharmaceuticals is a therapeutics company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros’ proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics and biomarkers. The Company’s founders are pioneers in gene control research and translation. Co-founded by Flagship Ventures and ARCH Venture Partners, Syros Pharmaceuticals is located in Cambridge, Mass.
Source: Syros Pharmaceuticals
Released November 5, 2015